Larimar Therapeutics Appoints John Harlow as President and COO

Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology firm, announced that John Harlow has been appointed President and Chief Operating Officer, effective September 29, 2026. He will report directly to CEO Carole Ben-Maimon.

The company’s lead investigational therapy, Nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia.

John Harlow brings over 25 years of experience in commercial operations, business development, and overall management within the biopharmaceutical sector.

His most recent role was Chief Commercial Officer at Esperion Therapeutics, where he oversaw commercial operations, business development, and global alliance management. He previously held the same CCO position at Melinta Therapeutics.

Earlier in his career, Harlow held executive leadership positions at Baudax Bio, Recro Pharma, and Endo Pharmaceuticals, and served in commercial and marketing leadership roles at Shionogi, Alpharma/King Pharmaceuticals, Novartis, and Janssen.

In the second quarter of 2026, the company reported a net loss of $32.8 million, or $0.30 per common share, compared with a net loss of $26.2 million, or $0.41 per common share, in the prior year.

As of June 30, 2026, the company held $156.3 million in cash, cash equivalents, and marketable securities, and projects a cash runway extending into the third quarter of 2027.

In June 2026, the company filed the first module of its rolling Biologics License Application (BLA) with the FDA, seeking accelerated approval for Nomlabofusp to treat Friedreich’s ataxia; the remaining modules are anticipated to be submitted in the second half of 2026.

LRMR has traded in the range of $2.72 to $6.42 over the past year, closing at $3.14 on Tuesday, a decline of 0.95%.

Source link